|
|
Post by mannmade on Jun 24, 2016 14:12:55 GMT -5
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jun 24, 2016 14:33:32 GMT -5
Lets not get ahead of ourselves...please ..after diluting 25% of the company
Kam: Will they have anything else to sell besides Afrezza?
Castagna: Not at this time, but we are actively looking for product acquisition opportunities as well as co-promote opportunities in 2017+. Short term we are focused on getting our launch right.
|
|
|
|
Post by sportsrancho on Jun 24, 2016 14:38:51 GMT -5
That is OMG excellent!
|
|
|
|
Post by petech on Jun 24, 2016 14:39:33 GMT -5
"Kam: Will they have anything else to sell besides Afrezza?
Castagna: Not at this time, but we are actively looking for product acquisition opportunities as well as co-promote opportunities in 2017+. Short term we are focused on getting our launch right."
Man, now THAT is what I call confidence. Mike is my hero.
|
|
|
|
Post by mannmade on Jun 24, 2016 14:44:24 GMT -5
What I like are his answers to all of the questions. They are straight forward, honest and intelligent and suggest that he does know what he is doing. And he sought them out, they did not come after him according to the article. Still need sales but we have much more insight to the process now than we ever did with Sanofi. Just mho and 2 cents worth...
|
|
|
|
Post by centralcoastinvestor on Jun 24, 2016 15:16:09 GMT -5
What I like are his answers to all of the questions. They are straight forward, honest and intelligent and suggest that he does know what he is doing. And he sought them out, they did not come after him according to the article. Still need sales but we have much more insight to the process now than we ever did with Sanofi. Just mho and 2 cents worth... I completely agree. Shareholders have screamed for transparency for some time now. I think Mike C. is doing a great job of that. In Mike's role, he not only has to understand the technical aspects of selling Afrezza but the public relations part as well. He is doing a great job of balancing those two necessities. Now if we can show any kind of week to week growth once the relaunch has begin, look out. Also, I don't know if everyone has noticed but Matt has stepped back from the spotlight to let Mike C. do his thing. I think that gives Matt more time on strategic issues. |
|
|
|
Post by centralcoastinvestor on Jun 24, 2016 15:18:27 GMT -5
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jun 24, 2016 15:21:37 GMT -5
What I like are his answers to all of the questions. They are straight forward, honest and intelligent and suggest that he does know what he is doing. And he sought them out, they did not come after him according to the article. Still need sales but we have much more insight to the process now than we ever did with Sanofi. Just mho and 2 cents worth... I like this comment from the Author and I think he writes fair pieces. In this case, it does not sound like Sanofi listened to the spirometry and titration issues being raised, so they never addressed them. No wonder they failed.I also liked the Mike reached out to them. At the end of the day the author is a blogger and he is paid by clicks. MNKD is click jackpot. So I am sure there is an off the record hand shake about them helping one another. Be fair and objective towards MNKD, and if you trash us this will be a one time interview. If you are fair we can continue this relationship. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jun 24, 2016 15:22:41 GMT -5
Hey sports, when did you graduate to postaholic? Isn't their some kind of ceremony for that?   Too bad there is not a like counter. She would have millions lol |
|
|
|
Post by sportsrancho on Jun 24, 2016 15:26:25 GMT -5
Hey sports, when did you graduate to postaholic? Isn't their some kind of ceremony for that? Too bad there is not a like counter. She would have millions lol I have a 1000 MNKD calls. I hope to yet:-))) |
|
|
|
Post by myocat on Jun 24, 2016 16:35:05 GMT -5
I like this observation;
" Since Sanofi has set the bar so low, MannKind’s success is likely to surprise Wall Street on the upside. However, in order for MannKind to become a home-run for investors and a paradigm shift for diabetics, the claim of “better A1Cs” needs to be supported with data so it can be openly used to market Afrezza."
|
|
|
|
Post by mnholdem on Jun 24, 2016 16:41:25 GMT -5
Hey sports, when did you graduate to postaholic? Isn't their some kind of ceremony for that? It's kind of a 'free masons' ritual, so I cannot divulge these secrets...but I can tell you that the dance that accompanies the chant involves a lot of head-shaking and rolling of the eyes.   When the Lead Global Moderator thumps his skull-staff three times, the ceremony is concluded. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jun 24, 2016 23:45:12 GMT -5
Hey sports, when did you graduate to postaholic? Isn't their some kind of ceremony for that? It's kind of a 'free masons' ritual, so I cannot divulge these secrets...but I can tell you that the dance that accompanies the chant involves a lot of head-shaking and rolling of the eyes. When the Lead Global Moderator thumps his skull-staff three times, the ceremony is concluded. Now that is awesome. Looks like a Carl Hiaasen character. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jun 25, 2016 0:04:59 GMT -5
Anyone else notice the Dexcom name dropping by Castagna? Twice.
Castagna:
"The other favorable trend out there is around the rapid growth of Dexcom and other CGMs which enable patients to measure their glucose real time via their iphone. When Afrezza got approved there were ~60,000-70,000 patients using a CGM and today there are over 150,000 people with diabetes in the US using these types of products. Overtime CGMs will become the standard of care where people will want to manage their glucose in real time to keep their sugars in a tight range without constant highs and lows. MannKind believes our brand will be critical in one’s ability to do this.
These new innovations are combining real time data with real time response feedback loops and allowing patients who have struggled for years to control their disease to actually gain back control of their life again. You can see their stories all over social media and if Dexcom has a successful FDA outcome in July, a patient could go from over 5,000 needle/lancet sticks a year to less than 1,000."
And then there is this:
Castagna:
"Not at this time, but we are actively looking for product acquisition opportunities as well as co-promote opportunities in 2017+.
Short term we are focused on getting our launch right."
Castagna for CEO.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 15, 2016 19:27:04 GMT -5
Lets not get ahead of ourselves...please ..after diluting 25% of the company Kam: Will they have anything else to sell besides Afrezza?
Castagna: Not at this time, but we are actively looking for product acquisition opportunities as well as co-promote opportunities in 2017+. Short term we are focused on getting our launch right.Product here is a spirometer.. so dont get your hopes up |
|
